Literature DB >> 11966713

Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.

M Fischer, E Fiedler, W C Marsch, J Wohlrab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11966713     DOI： 10.1046/j.1365-2133.2002.46833.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  22 in total

Review 1.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

2.  Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.

Authors:  Chuang-Wei Wang; Lan-Yan Yang; Chun-Bing Chen; Hsin-Chun Ho; Shuen-Iu Hung; Chih-Hsun Yang; Chee-Jen Chang; Shih-Chi Su; Rosaline Chung-Yee Hui; See-Wen Chin; Li-Fang Huang; Yang Yu-Wei Lin; Wei-Yang Chang; Wen-Lang Fan; Chin-Yi Yang; Ji-Chen Ho; Ya-Ching Chang; Chun-Wei Lu; Wen-Hung Chung
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

Review 3.  Skin manifestations of drug allergy.

Authors:  Michael R Ardern-Jones; Peter S Friedmann
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.

Authors:  Riichiro Abe; Tadamichi Shimizu; Akihiko Shibaki; Hideki Nakamura; Hirokazu Watanabe; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Authors:  Shoko Mori; Alanna Hickey; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2018-10-26       Impact factor: 11.527

Review 6.  Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.

Authors:  Stefanie Zimmermann; Peggy Sekula; Moritz Venhoff; Edith Motschall; Jochen Knaus; Martin Schumacher; Maja Mockenhaupt
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

7.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 8.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

Review 9.  Preparation of placental tissue transplants and their application in skin wound healing and chosen skin bullous diseases - Stevens-Johnson syndrome and toxic epidermal necrolysis treatment.

Authors:  Agnieszka Klama-Baryła; Ewa Rojczyk; Diana Kitala; Wojciech Łabuś; Wojciech Smętek; Katarzyna Wilemska-Kucharzewska; Marek Kucharzewski
Journal:  Int Wound J       Date:  2020-01-15       Impact factor: 3.315

10.  Boston Keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis.

Authors:  Jan G Dohlman; C Stephen Foster; Claes H Dohlman
Journal:  Digit J Ophthalmol       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.